Athersys Inc (ATHXQ)

[lemmy]

And then there was this b.s. pump on 13 January 2014 from the same journal:

"The stock is still “dramatically undervalued,” Mr. Kolbert said, noting that it should reach $10 a share within a year.

But if Athersys produces strong data in its Phase II trials, the company could blow away his $10 target, he said. Even $100 a share would be feasible if the stroke technology becomes a widely available product, Mr. Kolbert said, given that about two million people have strokes each year in the United States, Europe and Japan. Mr. Kolbert estimates Athersys would sell MultiStem treatments for $25,000 or more."

It "should" reach $10 within a year. Well, technically, from the date of that article, those pumpers have about a week and a half left. Fat chance.

http://www.crainscleveland.com/article/20140113/FREE/140119942/investors-perk-up-to-promise-of-athersys